> top > docs > PubMed:32178765 > annotations

PubMed:32178765 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-206 Sentence denotes Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
T2 207-218 Sentence denotes BACKGROUND:
T3 219-328 Sentence denotes Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors.
T4 329-534 Sentence denotes Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial.
T5 535-543 Sentence denotes METHODS:
T6 544-874 Sentence denotes This multicentre, double-blind, randomised, placebo-controlled, phase 3 trial was done at 86 sites in 13 countries across Asia, Australasia, Europe, and North America and enrolled adults with active psoriatic arthritis (at least three swollen and three tender joints; and C-reactive protein ≥0·3 mg/dL) despite standard therapies.
T7 875-1176 Sentence denotes Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis.
T8 1177-1266 Sentence denotes About 30% of study participants could have previously received one or two TNF inhibitors.
T9 1267-1526 Sentence denotes Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo.
T10 1527-1696 Sentence denotes The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 24 in all patients per assigned treatment group using non-responder imputation.
T11 1697-1756 Sentence denotes Safety was assessed in all patients per treatment received.
T12 1757-1842 Sentence denotes This trial is registered at ClinicalTrials.gov, NCT03162796 (active, not recruiting).
T13 1843-1852 Sentence denotes FINDINGS:
T14 1853-2054 Sentence denotes From Aug 28, 2017, to Aug 17, 2018, we screened 624 patients, of whom 381 were randomly assigned and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126).
T15 2055-2108 Sentence denotes 362 patients continued study treatment up to week 24.
T16 2109-2545 Sentence denotes The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p<0·0001).
T17 2546-2739 Sentence denotes Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo.
T18 2740-2907 Sentence denotes Up to week 24, one patient in the placebo group died from cardiac failure and two had serious infections; no guselkumab-treated patient died or had serious infections.
T19 2908-2923 Sentence denotes INTERPRETATION:
T20 2924-3070 Sentence denotes Guselkumab demonstrated a favourable benefit-risk profile and might be an effective treatment option for patients with active psoriatic arthritis.
T21 3071-3079 Sentence denotes FUNDING:
T22 3080-3113 Sentence denotes Janssen Research and Development.
T1 0-206 Sentence denotes Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
T2 207-218 Sentence denotes BACKGROUND:
T3 219-328 Sentence denotes Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors.
T4 329-534 Sentence denotes Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial.
T5 535-543 Sentence denotes METHODS:
T6 544-874 Sentence denotes This multicentre, double-blind, randomised, placebo-controlled, phase 3 trial was done at 86 sites in 13 countries across Asia, Australasia, Europe, and North America and enrolled adults with active psoriatic arthritis (at least three swollen and three tender joints; and C-reactive protein ≥0·3 mg/dL) despite standard therapies.
T7 875-1176 Sentence denotes Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis.
T8 1177-1266 Sentence denotes About 30% of study participants could have previously received one or two TNF inhibitors.
T9 1267-1526 Sentence denotes Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo.
T10 1527-1696 Sentence denotes The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 24 in all patients per assigned treatment group using non-responder imputation.
T11 1697-1756 Sentence denotes Safety was assessed in all patients per treatment received.
T12 1757-1842 Sentence denotes This trial is registered at ClinicalTrials.gov, NCT03162796 (active, not recruiting).
T13 1843-1852 Sentence denotes FINDINGS:
T14 1853-2054 Sentence denotes From Aug 28, 2017, to Aug 17, 2018, we screened 624 patients, of whom 381 were randomly assigned and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126).
T15 2055-2108 Sentence denotes 362 patients continued study treatment up to week 24.
T16 2109-2545 Sentence denotes The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p<0·0001).
T17 2546-2739 Sentence denotes Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo.
T18 2740-2907 Sentence denotes Up to week 24, one patient in the placebo group died from cardiac failure and two had serious infections; no guselkumab-treated patient died or had serious infections.
T19 2908-2923 Sentence denotes INTERPRETATION:
T20 2924-3070 Sentence denotes Guselkumab demonstrated a favourable benefit-risk profile and might be an effective treatment option for patients with active psoriatic arthritis.
T21 3071-3079 Sentence denotes FUNDING:
T22 3080-3113 Sentence denotes Janssen Research and Development.

yaoziqian_800_3

Id Subject Object Predicate Lexical cue
T1 0-10 CI denotes Guselkumab
T10 1518-1525 CI denotes placebo
T11 1967-1977 CI denotes guselkumab
T12 2001-2011 CI denotes guselkumab
T14 2225-2235 CI denotes guselkumab
T15 2351-2358 CI denotes placebo
T16 2427-2434 CI denotes placebo
T17 2617-2627 CI denotes guselkumab
T18 2672-2682 CI denotes guselkumab
T19 2731-2738 CI denotes placebo
T2 35-54 DP denotes psoriatic arthritis
T20 2774-2781 CI denotes placebo
T21 2849-2859 CI denotes guselkumab
T22 2924-2934 CI denotes Guselkumab
T23 3050-3069 DP denotes psoriatic arthritis
T3 238-257 DP denotes psoriatic arthritis
T4 329-339 CI denotes Guselkumab
T5 442-461 DP denotes psoriatic arthritis
T6 743-762 DP denotes psoriatic arthritis
T7 1156-1175 DP denotes psoriatic arthritis
T8 1420-1430 CI denotes guselkumab
T9 1453-1463 CI denotes guselkumab
T24 2038-2045 CI denotes placebo
T25 173-180 CI denotes placebo
T26 588-595 CI denotes placebo

Zierdiyeerkenaili_800_3

Id Subject Object Predicate Lexical cue
T1 0-10 CI denotes Guselkumab
T10 1420-1430 CI denotes guselkumab
T11 1453-1463 CI denotes guselkumab
T12 1967-1977 CI denotes guselkumab
T13 2001-2011 CI denotes guselkumab
T14 2225-2235 CI denotes guselkumab
T15 2617-2627 CI denotes guselkumab
T16 2672-2682 CI denotes guselkumab
T17 2849-2859 CI denotes guselkumab
T2 329-339 CI denotes Guselkumab
T3 2924-2934 CI denotes Guselkumab
T4 238-257 DP denotes psoriatic arthritis
T5 35-54 DP denotes psoriatic arthritis
T6 442-461 DP denotes psoriatic arthritis
T7 743-762 DP denotes psoriatic arthritis
T8 1156-1175 DP denotes psoriatic arthritis
T9 3050-3069 DP denotes psoriatic arthritis
T18 1518-1525 CI denotes placebo
T19 173-180 CI denotes placebo
T20 588-595 CI denotes placebo
T21 2038-2045 CI denotes placebo
T22 2351-2358 CI denotes placebo
T23 2427-2434 CI denotes placebo
T24 2731-2738 CI denotes placebo
T25 2774-2781 CI denotes placebo